Press releases

STOCKHOLM — December 6, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announces updated efficacy and safety data from the ongoing phase 2 ANCHOR combination study, following an oral presentation at the 62[nd] American Society of Hematology virtual annual meeting. The data showed that a triplet regimen with melflufen (INN melphalan flufenamide) plus dexamethasone in combination with daratumumab or bortezomib in heavily pretreated patients with relapsed refractory multiple myeloma, demonstrated encouraging activity, was well tolerated and had a similar safety profile as when used as a doublet regimen with only melflufen plus dexamethasone. The severe treatment related adverse events reported were primarily hematologic and were clinically manageable with dose reduction

Stockholm —December 4, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO), announces that an Extraordinary General Meeting was held today. Due to the extraordinary situation as a result of the COVID-19 pandemic, the extraordinary general meeting was carried out through postal voting, without any physical attendance. At the Extraordinary General Meeting, the following principal resolutions were passed

Stockholm —November 30, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the company’s incentive program

STOCKHOLM — November 24, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the company has finalized the program for the upcoming virtual capital markets day for investors, analysts and journalists on November 30[th], 2020. The program is available on the company´s website at: www.oncopeptides.com/en/calendar/ (https://oncopeptides.se/en/calendar/)

Summary Financial overview July 1 – September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3)

STOCKHOLM — November 5, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company will arrange a virtual capital markets day for investors, analysts and journalists on November 30[th], 2020. The program will be published on the company´s website during the week of November 23 at: www.oncopeptides.com/en/calendar/ (https://oncopeptides.se/en/calendar/)

STOCKHOLM — November 4, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focusing on the development of targeted therapies for difficult-to-treat hematological diseases, today announced that twelve abstracts, including one oral presentation, have been accepted for the upcoming virtual American Society of Hematology (ASH) meeting on December 5-8, 2020. Key clinical abstracts focus on data from the ongoing phase 1/2 ANCHOR combination study and the pivotal phase 2 HORIZON study. The preclinical abstracts further explore the mechanism of action of the proprietary peptide-drug conjugate platform in multidrug resistant models of multiple myeloma. The abstracts are published online today at https://www.hematology.org/meetings/annual-meeting/abstracts

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting on Friday 4 December 2020

STOCKHOLM — October 21, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the composition of the Nomination Committee for the Annual General Meeting 2021 has been established. The Nomination Committee consists of the following persons who together represent approximately 34 percent of the number of shares and votes in the company, based on the shareholder information by the end of September

STOCKHOLM — October 19, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 - a second drug candidate based on the proprietary Peptide Drug Conjugate platform (PDC)